

391071 PHARM ITP

TITLE : EFFECTIVENESS OF ARTEMETHER-LUMEFANTRINE
AS THE FIRST LINE DRUG IN TREATING
UNCOMPLICATED MALARIA AT THE NEW NYANZA
PROVINCIAL HOSPITAL – KISUMU.

INSTITUTION : THE KENYA POLYTECHNIC UNIVERSITY COLLEGE

CENTRE CODE : 4010024

COURSE : DIPLOMA IN PHARMACEUTICAL TECHNOLOGY

PRESENTER : ABUTO FRANCIS XAVIER

INDEX NO : 401002444

PAPER NO : 307A

COURSE CODE : Hs305105

COLLEGE NO : 105/01446

PRESENTED TO : KENYA NATIONAL EXAMINATION COUNCIL

SUPERVISOR : MR. ELIAZAR KARAN

SERIES : NOVEMBER 2007

ABSTRACT

This research was done to find out if AL which is used as the first line drug for treating uncomplicated malaria in Kenya is effective or to find out the causes of resistance if any and ways of stopping the increase in resistance in that case.

The research was carried out at the New Nyanza General Hospital within Kisumu town in Nyanza province where the residents around this region have increased endemity to malaria thus the research was expected to be a success.

The whole of the work involved in this was done within a period of four months, i.e. between the months of January to April 2007 and the participants included patients on AL and some hospital staff who took part in prescribing and dispensing in the hospital's in patient department. Structured questionnaires were used in interviewing the patients and for those who could not read or write, interviews was done by word of mouth using the same questions as in the questionnaires.

During the interview data was collected and then later analysed by the use of tables, bar graphs and pie charts where applicable.

It was later found out that in children below five years and pregnant mothers, there were high cases of complaints of non response to AL. It was also recommended that the young children be diagnosed accurately and patients be given enough advice on the use of AL.

Therefore it was concluded that AL is still an effective drug in treatment of uncomplicated malaria if all the required procedures mentioned are taken since there is no proof of resistance to this drug.